retrospective non-interventional study (NIS) that aims to describe the demographics, clinical characteristics, clinical outcomes, and treatment patterns, among patients receiving palbociclib for the treatment of HR+/HER2- metastatic/locally advanced breast cancer (BC)
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Demographical Characteristics of Participants
Timeframe: Upon BC diagnosis up to date of index treatment (from data collected and observed retrospectively between 01 January 2015 and 01 March 2019)
Demographical Characteristics of Participants: Biomarker status
Timeframe: Upon BC diagnosis up to date of index treatment (from data collected and observed retrospectively between 01 January 2015 and 01 March 2019)
Clinical Characteristics of Participants: Description of diagnosis
Timeframe: Upon BC diagnosis up to date of index treatment (from data collected and observed retrospectively between 01 January 2015 and 01 March 2019)
Number of patients receiving adjuvant therapies
Timeframe: Upon diagnosis of BC (from data collected and observed retrospectively between 01 January 2015 and 01 March 2019)
Number of participants receiving treatment for advanced/metastatic BC before and after palbociclib combination use
Timeframe: Upon diagnosis of metastatic/locally advanced HR+/HER2 BC for a maximum of 4 years approximately (from data collected and observed retrospectively between 01 January 2015 and 01 March 2019)
Number of participants with dose changes associated with palbociclib use
Timeframe: From 01 January 2015 to 30 September 2019
Number of participants to discontinue treatment associated with palbociclib use
Timeframe: From 01 January 2015 to 30 September 2019
Number of participant receiving supportive therapies while receiving palbociclib combination treatment
Timeframe: From 01 January 2015 to 30 September 2019
Proportion of patients who are progression free at multiple intervals
Timeframe: From date of index treatment to date of disease progression, date of death, or end of study whichever came first, assessed up to 57 months
Objective response rate (ORR)
Timeframe: From date of index treatment up to 57 months
Proportion of patients alive 1 and 2 years post palbociclib combination initiation depending on availability of follow-up data (if available)
Timeframe: From 01 January 2015 to 30 September 2019